Annual report pursuant to Section 13 and 15(d)

Consolidated Statement of Equity Consolidated Statement of Equity

v3.21.1
Consolidated Statement of Equity Consolidated Statement of Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Retained Earnings
Non-controlling Interests
Accumulated Other Comprehensive Income (Loss)
Directors
Common Stock
Employees
Common Stock
Executive Officers
Common Stock
Balance, beginning of period, shares at Mar. 31, 2018   32,492,339              
Balance, beginning of period at Mar. 31, 2018 $ 340,853 $ 32 $ 222,622 $ 148,812 $ 5,928 $ (36,541)      
Issuance of common stock in exercise of stock options, shares   37,906              
Issuance of common stock in exercise of stock options 396   396            
Issuance of restricted stock as deferred compensation to employees and directors, shares             20,064    
Issuance of common stock in lieu of compensation, shares               51,775 22,116
Issuance of common stock as deferred compensation to employees 1 $ 1              
Stock compensation expense 4,148   4,148            
Excess tax deduction from stock options (598)   (598)            
Net income (loss) 22,756     22,756          
Foreign curency translation adjustment (13,233)         (13,233)      
Other 825         825      
Purchase of non-controlling interest (947)     (947)          
Distribution to non-controlling interest (947)     (947)          
Remeasurement of non-controlling interest     (3,528)   3,528        
Purchase of non-controlling interest (5,665)       (5,665)        
Income attributable to non-controlling interests 413       413        
Balance, end of period, shares at Mar. 31, 2019   32,624,200              
Balance, end of period at Mar. 31, 2019 348,949 $ 33 223,040 170,621 4,204 (48,949)      
Issuance of common stock in exercise of stock options, shares   159,062              
Issuance of common stock in exercise of stock options 1,016   1,016            
Issuance of restricted stock as deferred compensation to employees and directors, shares             26,608    
Issuance of common stock in lieu of compensation, shares               59,570 47,378
Issuance of common stock as deferred compensation to employees 0 $ 0              
Stock compensation expense 4,960   4,960            
Excess tax deduction from stock options (969)   (969)            
Net income (loss) 11,938     11,938          
Foreign curency translation adjustment (15,485)         (15,485)      
Interest rate swap 540         540      
Purchase of non-controlling interest (4,508)       (4,508)        
Distribution to non-controlling interest (4,508)       (4,508)        
Remeasurement of non-controlling interest     (306)   306        
Income attributable to non-controlling interests $ (2)       (2)        
Balance, end of period, shares at Mar. 31, 2020 32,916,818 32,916,818              
Balance, end of period at Mar. 31, 2020 $ 346,439 $ 33 227,741 182,559 0 (63,894)      
Issuance of common stock in exercise of stock options, shares   97,156              
Issuance of common stock in exercise of stock options 629   629            
Issuance of restricted stock as deferred compensation to employees and directors, shares             52,098    
Issuance of common stock in lieu of compensation, shares               88,254 71,482
Issuance of common stock as deferred compensation to employees 0 $ 0              
Stock compensation expense 3,728   3,728            
Excess tax deduction from stock options (784)   (784)            
Net income (loss) 1,165     1,165          
Foreign curency translation adjustment 28,615         28,615      
Other (631)   (8)     (640)      
Income attributable to non-controlling interests $ 0                
Balance, end of period, shares at Mar. 31, 2021 33,225,808 33,225,808              
Balance, end of period at Mar. 31, 2021 $ 379,161 $ 33 $ 231,322 $ 183,725 $ 0 $ (35,919)